Literature DB >> 15095277

Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.

Frédéric Lavie1, Corinne Miceli-Richard, Jeanine Quillard, Sophie Roux, Philippe Leclerc, Xavier Mariette.   

Abstract

Primary Sjögren's syndrome (pSS) is an autoimmune disorder characterized by lymphocytic infiltration of the salivary glands. Most of the infiltrating cells are T cells, but other features of the disease include polyclonal B-cell activation, systemic production of autoantibodies, and increased risk of developing B-cell non-Hodgkin's lymphoma. Recently, a new tumour necrosis factor, the B-cell activating factor (BAFF; also known as BLyS), has been implicated in the polyclonal activation of B cells. Using immunohistochemistry, this study evaluated BAFF expression in labial salivary gland biopsies from 14 patients with pSS, 14 normal controls, and two patients with sarcoidosis. Labial salivary gland samples from seven patients with pSS, seven controls, and one patient with sarcoidosis were double-stained using indirect immunofluorescence. RT-PCR analysis was also performed on lip biopsy samples from two patients and two controls. In all 14 pSS specimens, infiltrating inflammatory cells strongly expressed BAFF protein, as did some ductal epithelial cells, but acinar cells were negative. Some B cells were present in the vicinity of the BAFF-positive cells. In the 14 normal labial salivary glands, some ductal cells were moderately positive, but acinar cells were negative. In the labial salivary glands from the two patients with sarcoidosis, infiltrating lymphocytes were not stained. BAFF mRNA expression was confirmed by RT-PCR in salivary glands from pSS patients. Double immunofluorescence revealed T cells and macrophages to be the main cell types expressing BAFF in salivary glands from pSS patients. In conclusion, BAFF may be expressed by T cells at the site of autoimmune damage and could play a role in the pathogenesis of pSS, particularly by triggering the activation of self-antigen-driven autoimmune B cells. Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095277     DOI: 10.1002/path.1533

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  59 in total

1.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

2.  Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  Jérémie Sellam; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Marc Ittah; Frédéric Lavie; Christine Lacabaratz; Nicolas Gestermann; Alexis Proust; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

3.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

Review 4.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 5.  Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease.

Authors:  Cuong Q Nguyen; Ammon B Peck
Journal:  Ocul Surf       Date:  2009-01       Impact factor: 5.033

6.  Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept.

Authors:  N Roescher; J L Vosters; G Alsaleh; P Dreyfus; S Jacques; G Chiocchia; J Sibilia; P P Tak; J A Chiorini; X Mariette; Jacques-Eric Gottenberg
Journal:  Mol Ther       Date:  2013-12-05       Impact factor: 11.454

7.  Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.

Authors:  Luca Quartuccio; Martina Fabris; Sara Salvin; Marta Maset; Ginevra De Marchi; Salvatore De Vita
Journal:  Int J Rheumatol       Date:  2010-01-28

8.  Genome-wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus.

Authors:  Danielle Malheiros; Rodrigo A Panepucci; Ana M Roselino; Amélia G Araújo; Marco A Zago; Maria Luiza Petzl-Erler
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

9.  B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation.

Authors:  Yu Hee Kim; Bong Hyuk Choi; Hyae Gyeong Cheon; Myoung Sool Do
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

Review 10.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.